These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 34753149)
1. Advances in the Era of Direct-Acting Antivirals for Hepatitis C in Patients with Unresectable Hepatocellular Carcinoma. Chen LS; Lee SW; Yang SS; Tsai HJ; Lee TY Dig Dis; 2022; 40(5):616-624. PubMed ID: 34753149 [TBL] [Abstract][Full Text] [Related]
2. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. Chi CT; Chen CY; Su CW; Chen PY; Chu CJ; Lan KH; Lee IC; Hou MC; Huang YH J Microbiol Immunol Infect; 2021 Jun; 54(3):385-395. PubMed ID: 31771822 [TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents. Kao YT; Liu YC; Cheng YT; Wen YW; Hsieh YC; Hsu CE; Su CW; Tai JC; Chen YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS Viruses; 2024 Sep; 16(9):. PubMed ID: 39339961 [TBL] [Abstract][Full Text] [Related]
4. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005 [TBL] [Abstract][Full Text] [Related]
5. Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma. Lee SW; Chen LS; Yang SS; Huang YH; Lee TY Viruses; 2022 Oct; 14(11):. PubMed ID: 36366415 [TBL] [Abstract][Full Text] [Related]
6. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591 [TBL] [Abstract][Full Text] [Related]
7. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876 [TBL] [Abstract][Full Text] [Related]
10. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831 [TBL] [Abstract][Full Text] [Related]
11. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents. Ohama H; Hiraoka A; Tada T; Kariyama K; Itobayashi E; Tsuji K; Ishikawa T; Toyoda H; Hatanaka T; Kakizaki S; Naganuma A; Tada F; Tanaka H; Nakamura S; Nouso K; Tanaka K; Kumada T; J Gastroenterol Hepatol; 2024 Jul; 39(7):1394-1402. PubMed ID: 38602340 [TBL] [Abstract][Full Text] [Related]
12. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. Ikenaga H; Uchida-Kobayashi S; Tamori A; Odagiri N; Yoshida K; Kotani K; Motoyama H; Kozuka R; Kawamura E; Hagihara A; Fujii H; Enomoto M; Kawada N J Viral Hepat; 2022 Jan; 29(1):52-59. PubMed ID: 34695288 [TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119 [TBL] [Abstract][Full Text] [Related]
15. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183 [TBL] [Abstract][Full Text] [Related]
16. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients. Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Luo JC; Lee IC; Chi CT; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC J Chin Med Assoc; 2024 Apr; 87(4):357-368. PubMed ID: 38180018 [TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group. Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866 [TBL] [Abstract][Full Text] [Related]
19. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E; Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138 [TBL] [Abstract][Full Text] [Related]
20. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]